Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy

BackgroundPharmaco-invasive therapy (PIT), combining thrombolysis and percutaneous coronary intervention, was a potential complement for primary percutaneous coronary intervention (pPCI), while bleeding risk was still a concern.ObjectivesThis study aims to compare the efficacy and safety outcomes of...

Full description

Bibliographic Details
Main Authors: Kaiyin Li, Bin Zhang, Bo Zheng, Yan Zhang, Yong Huo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.813325/full
_version_ 1818338167005118464
author Kaiyin Li
Bin Zhang
Bo Zheng
Bo Zheng
Yan Zhang
Yan Zhang
Yong Huo
author_facet Kaiyin Li
Bin Zhang
Bo Zheng
Bo Zheng
Yan Zhang
Yan Zhang
Yong Huo
author_sort Kaiyin Li
collection DOAJ
description BackgroundPharmaco-invasive therapy (PIT), combining thrombolysis and percutaneous coronary intervention, was a potential complement for primary percutaneous coronary intervention (pPCI), while bleeding risk was still a concern.ObjectivesThis study aims to compare the efficacy and safety outcomes of PIT and pPCI.MethodsA systematic search for randomized controlled trials (RCTs) and observational studies were conducted on Pubmed, Embase, Cochrane library, and Scopus. RCTs and observational studies were all collected and respectively analyzed, and combined pooled analysis was also presented. The primary efficacy outcome was short-term all-cause mortality within 30 days, including in-hospital period. The primary safety outcome was 30-day trial-defined major bleeding events.ResultsA total of 26,597 patients from 5 RCTs and 12 observational studies were included. There was no significant difference in short-term mortality [RCTs: risk ratio (RR): 1.14, 95% CI: 0.67–1.93, I2 = 0%, p = 0.64; combined results: odds ratio (OR): 1.09, 95% CI: 0.93–1.29, I2 = 0%, p = 0.30] and 30-day major bleeding events (RCTs: RR: 0.44, 95% CI: 0.07–2.93, I2 = 0%, p = 0.39; combined results: OR: 1.01, 95% CI: 0.53–1.92, I2 = 0%, p = 0.98). However, pPCI reduced risk of in-hospital major bleeding events, stroke and intracranial bleeding, but increased risk of in-hospital heart failure and 30-day heart failure in combined analysis of RCTs and observational studies, despite no significant difference in analysis of RCTs.ConclusionPharmaco-invasive therapy could be an important complement for pPCI in real-world clinical practice under specific conditions, but studies aiming at optimizing thrombolysis and its combination of mandatory coronary angiography are also warranted.
first_indexed 2024-12-13T15:06:48Z
format Article
id doaj.art-5d728d4b82234342b5d1e61fae356957
institution Directory Open Access Journal
issn 2297-055X
language English
last_indexed 2024-12-13T15:06:48Z
publishDate 2022-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj.art-5d728d4b82234342b5d1e61fae3569572022-12-21T23:40:59ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-03-01910.3389/fcvm.2022.813325813325Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive TherapyKaiyin Li0Bin Zhang1Bo Zheng2Bo Zheng3Yan Zhang4Yan Zhang5Yong Huo6Department of Cardiology, Peking University First Hospital, Beijing, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing, ChinaInstitute of Cardiovascular Disease, Peking University First hospital, Beijing, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing, ChinaInstitute of Cardiovascular Disease, Peking University First hospital, Beijing, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing, ChinaBackgroundPharmaco-invasive therapy (PIT), combining thrombolysis and percutaneous coronary intervention, was a potential complement for primary percutaneous coronary intervention (pPCI), while bleeding risk was still a concern.ObjectivesThis study aims to compare the efficacy and safety outcomes of PIT and pPCI.MethodsA systematic search for randomized controlled trials (RCTs) and observational studies were conducted on Pubmed, Embase, Cochrane library, and Scopus. RCTs and observational studies were all collected and respectively analyzed, and combined pooled analysis was also presented. The primary efficacy outcome was short-term all-cause mortality within 30 days, including in-hospital period. The primary safety outcome was 30-day trial-defined major bleeding events.ResultsA total of 26,597 patients from 5 RCTs and 12 observational studies were included. There was no significant difference in short-term mortality [RCTs: risk ratio (RR): 1.14, 95% CI: 0.67–1.93, I2 = 0%, p = 0.64; combined results: odds ratio (OR): 1.09, 95% CI: 0.93–1.29, I2 = 0%, p = 0.30] and 30-day major bleeding events (RCTs: RR: 0.44, 95% CI: 0.07–2.93, I2 = 0%, p = 0.39; combined results: OR: 1.01, 95% CI: 0.53–1.92, I2 = 0%, p = 0.98). However, pPCI reduced risk of in-hospital major bleeding events, stroke and intracranial bleeding, but increased risk of in-hospital heart failure and 30-day heart failure in combined analysis of RCTs and observational studies, despite no significant difference in analysis of RCTs.ConclusionPharmaco-invasive therapy could be an important complement for pPCI in real-world clinical practice under specific conditions, but studies aiming at optimizing thrombolysis and its combination of mandatory coronary angiography are also warranted.https://www.frontiersin.org/articles/10.3389/fcvm.2022.813325/fullST-elevation myocardial infarction (STEMI)primary percutaneous coronary intervention (PPCI)pharmaco-invasive therapymortalityhemorrhageheart failure
spellingShingle Kaiyin Li
Bin Zhang
Bo Zheng
Bo Zheng
Yan Zhang
Yan Zhang
Yong Huo
Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
Frontiers in Cardiovascular Medicine
ST-elevation myocardial infarction (STEMI)
primary percutaneous coronary intervention (PPCI)
pharmaco-invasive therapy
mortality
hemorrhage
heart failure
title Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_full Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_fullStr Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_full_unstemmed Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_short Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_sort reperfusion strategy of st elevation myocardial infarction a meta analysis of primary percutaneous coronary intervention and pharmaco invasive therapy
topic ST-elevation myocardial infarction (STEMI)
primary percutaneous coronary intervention (PPCI)
pharmaco-invasive therapy
mortality
hemorrhage
heart failure
url https://www.frontiersin.org/articles/10.3389/fcvm.2022.813325/full
work_keys_str_mv AT kaiyinli reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT binzhang reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT bozheng reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT bozheng reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT yanzhang reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT yanzhang reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT yonghuo reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy